Structural and nonstructural regions of the HCV-encoded polyprotein have been expressed in recombinant yeast, bacteria, or insect cells and used to capture and measure reactive antibodies circulating in different individuals. The putative nucleocapsid protein (C) and nonstructural proteins 3-5 (NS3-NS5) were found to contain the most immunodominant epitopes. The NS3, NS4, and C regions were expressed in yeast in the form of a fused, chimeric polyprotein (C25) and a capture assay for reactive antibody was developed. This anti-C25 assay detects all previously identified HCV-seropositive cases and provides a substantially more sensitive diagnostic for both acute and chronic HCV infections than the current anti-C100-3 (NS4) assay. Anti-C25 was detected more frequently than anti-C100-3 in chronic, transfusion-associated non-A, non-B hepatitis patients from the United States (95% vs. 71%) and Japan (98% vs. 82%), in cryptogenic cirrhosis patients from the United States (62% vs. 28%), and in hepatitis B surface antigen-negative cases of hepatocellular carcinoma from Japan (83% vs. 63%). These data indicate that HCV has a greater role in these liver diseases than was previously thought. In volunteer United States blood donors sampled following the introduction of anti-C100-3 screening, the prevalence of anti-C25 and anti-C100-3 was 0.5% and 0.08%, respectively.
source of viral isolate. Although HCV is a unique infectious agent, the existence of limited nucleotide and amino acid sequence homologies with the pestiviruses and flaviviruses indicates that HCV is a distant relative of these viruses (2) . This hypothesis is supported by the observed similarity in the hydrophobicity profiles of these three kinds of viral polyproteins and in the apparent N-terminal location of structural proteins (2) .
To produce a specific assay for NANBH, a small region of the HCV genome was first cloned in recombinant yeast that then expressed large amounts of the HCV-encoded polypeptide. After purification, this HCV polypeptide, termed C100-3, was used to capture and measure reactive antibody circulating in infected individuals (5) . Data obtained with this assay indicated that HCV was the major cause of both transfusion-associated NANBH and sporadic, communityacquired NANBH (5) . Subsequent data derived from using either the original RIA format or the subsequent commercial ELISA configuration have confirmed these conclusions (refs. 6-12; for review see ref. 13 ) and demonstrated the efficacy of these assays in screening out infectious blood donations (9, 10, (14) (15) (16) . Although the anti-C100-3 assay is a highly valuable clinical and screening tool, it is not capable of detecting all infectious blood donors (9, 10, (14) (15) (16) and its use in diagnosis is limited by the delay that is often observed prior to seroconversion (9, 12) . The C100-3 antigen represents only about 12% of the coding capacity of HCV and corresponds mainly with the nonstructural protein 4 (NS4) region of the flaviviruses (2, 13) . We now report on the immunoreactivity of recombinant HCV polypeptides derived from many different regions of the HCV polyprotein, including that of a chimeric recombinant polyprotein, C25, comprising the immunodominant components evident in both the structural and nonstructural regions. Data obtained by using C25 as a capture antigen for circulating HCV antibodies warrant a reevaluation of the role of HCV in liver disease.
MATERIALS AND METHODS
Expression and Purification of Recombinant HCV Antigens. The C22 (119 aa), el (130 aa), ns5 (942 aa), and chimeric C25 (858 aa) antigens (see Fig. 1 for relative location) were expressed as internal antigens within the yeast Saccharomyces cerevisiae as C-terminal fusions with human superoxide dismutase (SOD) by using methods described previously for the generation of the C100-3 (363 aa) antigen (5, 17) . The C33C antigen (266 aa; Fig. 1 ) was expressed as an internal SOD fusion polypeptide in Escherichia coli by methods described earlier for the synthesis of the 5-1-1 antigen (1). Following cell breakage and centrifugation, the insoluble SOD fusion polypeptides were extracted from the cell pellets with either 5 M urea or 1% SDS and purified by a combination ofion-exchange chromatography (Q and S Sepharose) and gel filtration (Sephacryl S-300 HR). The e2 antigen (257 aa; Fig.  1 ) was expressed as a secreted protein in Spodoptera frugiperda insect cells by cloning the E2 gene segment downstream ofthe interleukin 2 signal sequence (18) in a derivative of the baculovirus vector pAc373 (18, 19) . The e2 antigen was Abbreviations: HCV, hepatitis C virus; NANBH, non-A, non-B hepatitis; SOD, superoxide dismutase; aa, amino acid(s); HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma. tTo whom reprint requests should be addressed.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Fig. 1 indicates the relative location within the HCV-encoded polyprotein precursor of the various recombinant-derived viral polypeptides used as capture antigens for circulating antibody. The C22 polypeptide corresponds to the N-terminal region of the presumed nucleocapsid protein (C) (2) . The el and e2 recombinant polypeptides represent substantial parts of the putative envelope glycoproteins El and E2, respectively (2, 13, 20, 21) . Since el was expressed internally in yeast, this recombinant product was a nonglycosylated derivative. In contrast, e2 was expressed and secreted from insect cell cultures as a partially glycosylated polypeptide. The C33C polypeptide was synthesized in recombinant bacteria and is derived from most of the NS3 region that appears to encode both a viral protease and a helicase (2) . The ns5 polypeptide is the product of the majority of the NS5 gene, which appears to encode the viral replicase (2) . Each recombinant HCV polypeptide was purified to homogeneity and then used to capture and measure reactive antibody circulating in different individuals. Immunoassays measuring anti-C100-3 antibody were also performed on the same serum samples. Initially, the prevalence of the various HCV antibodies in 158 paid plasma donors from the United States was determined ( Table 1 ). The prevalence of HCV antibody varied between 11% and 19% depending on the particular capture antigen used, with the highest prevalence observed with the C33C polypeptide, followed by the C22, ns5, and C100-3 polypeptides, respectively (Table 1) . A similar estimate of the frequency of anti-C100-3 in commercial plasma donors was reported recently and shown to be -30-fold higher than that in volunteer donors (22) . A substantially lower prevalence of antibody to both ofthe putative envelope proteins was observed ( Table 1 ). The combined prevalence of HCV antibody detected with any of the recombinant HCV polypeptides was 20%o. This represents a 23% increase in detection of HCV antibody when compared with the anti-C100-3 prevalence. Assays were then performed on serum samples obtained from 38 United States patients clinically diagnosed with transfusion-associated chronic NANBH. The prevalence of HCV antibody varied from 58% to 95%, with the highest detection rate obtained for the C33C polypeptide, followed by the C22 polypeptide (Table 1) . Again, the lowest prevalence of antibody recorded was obtained using either the el or e2 antigens, with 58-61% of this patient population being positive to either antigen. The combined detection rate of HCV antibody for any of the recombinant polypeptides was 95%, which represents a 33.3% increase over the prevalence of anti-C100-3 in the same population (Table 1) . When serum samples from 81 patients from the United States diagnosed with cryptogenic cirrhosis were assayed, the combined prevalence of HCV antibody was 62%, compared with a value of only 28% obtained with the anti-C100-3 assay alone (Table 1) . This indicates that HCV may play a much greater role in this liver disease than was evident from data obtained by the initial commercial anti-C100-3 immunoassay. As in the paid blood donors and transfusion-associated chronic NANBH cases, the most common HCV antibodies observed were to the C22, C33C, and ns5 polypeptides (Table 1) . Unlike the previous two study populations, however, anti-e2 was found more often than anti-C100-3 in cases of cryptogenic cirrhosis. Importantly, all samples positive for HCV antibody in Table 1 were found to be positive for at least two (usually three to four) of the recombinant HCV polypeptides. Furthermore, all positive samples could be detected in either the C22, C33C, or C100-3 antibody assays. In view of these observations, the recombinant chimeric polyprotein C25 was designed to fuse the immunodominant C22 and C33C regions together with the existing C100-3 diagnostic antigen in order to create a single, more sensitive capture antigen to diagnose HCV infections. In this process, the segment between the C33C and C100-3 regions was also expressed as part of this yeast recombinant product (Fig. 1) . The selection of these particular immunogenic regions was also supported by the observation that the C, NS3, and NS4 gene products appear to be the three most highly conserved protein domains among HCV isolates from around the world (reviewed in ref. 20) . Following purification to homogeneity, C25 was used as a capture antigen for antibodies. All of the HCV antibodypositive samples previously identified in the blood donor and patient groups were also found positive in the anti-C25 assay ( Table 1) . The recombinant C25 polypeptide therefore is a convenient and substantially more sensitive capture antigen than the original C100-3 polypeptide(s). A total of 3615 recent volunteer blood donors from the United States were tested for the presence of antibody to the C22, C33C, and C100-3 antigens by using the individual anti-C22, anti-C33C, and anti-C100-3 assays; 18 samples were scored positive. Ofthese positive samples, 18 contained anti-C33C antibody, and 16 were positive for anti-C22. Since the volunteer blood donor population in the United States has been screened for anti-C100-3 since mid-1990, the prevalence of anti-C100-3 was expected to be low, as was actually observed ( Table 2 ). The anti-C25 assay detected all 18 positive samples ( Table 2) .
The specificity of the anti-C25 assay was further investigated in assays of serum samples obtained in 1990 and 1991 from 1053 volunteer blood donors from the United States. 4.0-5.0, 2; OD >7.0, 4) and, when retested in separate immunoassays, were positive for antibodies to at least two of the C25, C33C, C100-3, C22, and ns5 antigens. When tested for reaction to C22, C33C, C100-3, and 5-1-1 recombinant antigens that had been immunoblotted separately onto nitrocellulose strips (23), 7 of these 8 samples showed positive binding to at least two antigens. The eighth sample bound to immunoblotted C22 only and was therefore considered "indeterminate." In addition, 13 sera positive for rheumatoid factor were tested in the anti-C25 assay and all were found negative.
The recombinant HCV antigens used in this study are derived from the original HCV-1 isolate from the United States, which constitutes the prototype of group I viruses (2, 20) . It was therefore of importance to test the crossreactivity of these HCV-1 antigens in cases of NANBH from Japan, where the divergent group II viruses predominate (reviewed in ref. 20) . Of 50 Japanese patients diagnosed with chronic NANBH, 41 (82%) were found positive for anti-C100-3 whereas 49 (98%) were found positive for anti-C25 antibodies, which represents a 19.5% increase in sensitivity.
The prevalence of anti-C100-3 and anti-C25 antibodies in Japanese cases of hepatocellular carcinoma (HCC) was also determined. Of 268 cases of primary HCC, which lacked HBsAg and antibody to hepatitis B core antigen and in which replication of hepatitis B virus (HBV) was therefore absent, the prevalence ofanti-C100-3 was found to be 63% (169/268), which is similar to previous estimates (24, 25) . However, an additional 54 patients (20%) were also scored positive in the anti-C25 assay, giving rise to an overall anti-C25 prevalence of 83% in this patient population. These findings suggest that in Japan, HCV is the predominant cause of HBsAg-negative cases of HCC and that in accord with the data described above, the C25 antigen affords a more sensitive assay for HCV infection.
The time required for detectable seroconversion to various recombinant HCV polypeptides was investigated in 10 prospectively followed cases of clinically diagnosed, posttransfusion HCV infections in the United States that all led to chronic disease. In 7 of these cases, a much earlier diagnosis of HCV infection could be made with the anti-C25 assay. In the remaining 3 cases, seroconversion to anti-C25 and anti-C100-3 was detected at about the same time (Fig. 2) . In the 10 patients studied, the mean time for seroconversion following transfusion was 15.3 weeks (range, 7.4-30.6 weeks) and 23.9 weeks (7.4-53.4 weeks) for anti-C25 and anti-C100-3, respectively. The mean time for seroconversion following onset of disease (i.e., the initial increase in alanine aminotransferase) was weeks (0.4-45.4 weeks) for anti-C25 and anti-C100-3, respectively. Of the 7 cases showing earlier seroconversion to anti-C25, initial seroconversion to C33C and C22 epitopes occurred in 5 and 4 patients, respectively. In two patients, the earliest seroconversion event occurred simultaneously to epitopes in both C33C and C22 polypeptides (Fig. 2) .
DISCUSSION
With the exception of NS2, all ofthe presumed structural and nonstructural protein domains of HCV were expressed in a heter'ologous expression system and shown to be capable of binding antibody circulating in infected individuals. Clearly, the HCV genome encodes antibody-binding epitopes in most (ifnot all) of its viral proteins. Earlier studies have proven the efficacy of the recombinant C-100-3 antigen in diagnosing HCV infections (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) , but the data reported here show that the recombinant nucleocapsid (C), NS3, and NS5 gene products are all more efficient as capture antigens than the C-100-3 (primarily NS4) polypeptide (Table 1 ). The high immunogenicity of the C gene product has also been reported by others (26, 27) . Using a combination of the C22, C33C, and C100-3 capture antigens, all HCV antibody-positive samples could be detected (Table 1 and Fig. 2) , an observation that has led recently to the commercial production ofa second-generation anti-HCV assay incorporating all of the epitopes inherent in these proteins. In this commercial format, the C22 antigen is mixed with the C100-3 antigen and a fusion polypeptide comprising the C33C, C100-3, and intervening regions (Fig.  1) . However, we have now demonstrated that when these epitopes are presented in the form of a single chimeric polyprotein, all previously identified anti-HCV positive samples can be detected (Tables 1 and 2 ; Fig. 2) . Thus, an optimal anti-HCV test can be produced through the use of one convenient, recombinant capture antigen.
When used for screening volunteer blood donors from the United States, the anti-C25 assay allowed the clear distinction of positive samples and detected positive donors at a frequency of0.76% (8/1053). When donors were sampled -1 year after the introduction into the United States of routine anti-C100-3 screening and subsequent deferral of positive donors, the prevalence of antibodies to the constituent components of C25 was found to be 0.5% (18/3615; Table 2 ). The low prevalence of anti-C100-3 in this population (0.08%; Table 2 ) is presumably a consequence ofthe prior anti-C100-3 screening, and these data emphasize the importance of the anti-C25 assay in identifying not only individuals positive for anti-C100-3 but also an additional subgroup of donors who have been exposed to HCV but who have not seroconverted to anti-C100-3. From the data in Table 2 , it can be estimated that an additional 0.41% (15/3615) of volunteer blood donors in the United States could now be scored positive for exposure to HCV over and above those positive for anti-C100-3.
In the light of growing evidence for substantial heterogeneity of the HCV genome (for review see ref. 20) , it was of importance to determine the degree of crossreactivity of the constituent epitopes in the C25 antigen. This was addressed by assaying samples from patients in Japan, where HCV genotypes distinct from the United States isolates appear to predominate (refs. 3, 4, and 28; for review see ref. 20) . Of 50 Japanese patients diagnosed with transfusion-associated chronic NANBH, 49 (98%) had antibodies that crossreacted with the C25 antigen. Comparative sequence analysis of the common United States (group I) and Japanese (group II) HCV isolates indicates that the most highly conserved protein domains are the C, NS3, and NS4 regions, showing predicted amino acid homologies of 97-98%, 91-92%0, and 90-93%, respectively (20) . Since these domains are constituents of the C25 capture antigen, the high level of amino acid sequence conservation probably accounts for the nearly complete detection of HCV antibody in Japanese patients with chronic NANBH.
The advent of the more sensitive test for HCV antibody described here allows a reevaluation of the role of HCV in liver disease. Compared with the C100-3 antigen, the use of C25 (or a combination of its three constituent antigens) increases the frequency of diagnosis of HCV in transfusionassociated chronic NANBH by 20-33%, leading to a prevalence of 95-98% (Table 1 ; see also above). Clearly, the data obtained here with the anti-C25 assay indicate that HCV is the predominant cause of transfusion-associated, chronic NANBH. The few seronegative cases may be due either to some other cause of liver disease or to HCV infections that fail to induce antibody to viral proteins (29) . Similarly, data obtained with the anti-C25 assay indicate that in Japan, HCV is the predominant cause of HBsAg-negative, primary HCC. Overall, HCV appears to be a more common cause of HCC in Japan than HBV (25) . In the United States, HBs antigenemia is associated with 15-52% of HCC patients (30-33) and co n en a) CIO E Proc. Natl. Acad. Sci. USA 89 (1992) Proc. Natl. Acad. Sci. USA 89 (1992) 10015 the prevalence of anti-C100-3 in HBsAg-negative cases of HCC has been reported to vary from 13% to 53% (34, 35) . Because of the 32% increase in sensitivity of detection of HCV antibody in Japanese HCC cases for the C25 antigen as compared with the C100-3 antigen, it may be anticipated that HCV will be found to be more closely associated with HCC in the United States than previously envisaged from the use of the initial anti-C100-3 assay, to the extent that HCV may be a major risk factor for HCC in the United States. On a similar note, the use of the anti-C25 assay has revealed that HCV may be a major cause of cryptogenic cirrhosis in the United States (Table 1) .
Apart from the utility of this more sensitive assay for HCV antibody in diagnosing chronic liver disease, it will also have a major impact in diagnosing acute hepatitis. The potential lag time required for seroconversion to anti-C100-3 is well known (5, 9, 12) , but by using the epitopes inherent in the C and NS3 protein domains, this lag time can be substantially reduced in most cases (Fig. 2) . Interestingly, there is substantial variation in the antigen targeting of the immune response during HCV infection, unlike the situation with HBV, for example, where an antibody response to the HBV core protein is usually the earliest humoral immune response (36) . In conclusion, the screening and diagnosis of HCV infections will be substantially enhanced through the use of the multiple epitopes encoded by the chimeric C25 capture antigen, as will the magnitude of the role of HCV infections in liver disease. The development of additional assays for viral RNA and antigen should also be ofgreat value, as will the development of virus-specific assays in order to investigate the potential influence of viral genotype on pathogenicity.
